The Joe Rogan ExperienceJoe Rogan Experience #1175 - Chris Kresser & Dr. Joel Kahn
CHAPTERS
- 0:02 – 4:39
Meet the debaters: a preventive vegan cardiologist vs. a functional medicine clinician
Joe introduces Dr. Joel Kahn as the vegan/plant-based cardiology voice and Chris Kresser as a functional medicine practitioner with a personal history of chronic illness. Both outline their training, clinical focus, and why they care about diet as medicine.
- •Dr. Joel Kahn’s cardiology background, decades-long veganism, and preventive cardiology practice
- •Chris Kresser’s functional medicine work, training programs, and recovery from chronic illness
- •Kresser’s earlier vegetarian/macrobiotic vegan phase and why he moved away from it
- •Shared emphasis on lifestyle factors beyond food (sleep, stress, activity)
- 4:39 – 8:40
No one-size-fits-all diet: quality, context, and “nutritionism”
The conversation quickly converges on a key premise: asking for the single optimal diet for everyone is the wrong question. Kresser critiques “nutritionism” and the tendency to reduce diets to macronutrient percentages rather than food quality and context.
- •Agreement that individuals differ in needs and responses
- •Critique of reducing diets to macros (fat/carbs/protein) instead of whole-food patterns
- •Examples showing that the same macro ratio can describe radically different diets (pizza vs. olive oil/avocados)
- •Call for more precise language: refined vs. complex carbs, processed vs. whole-food fats, animal vs. plant protein
- 8:40 – 11:51
What epidemiology is—and why it’s controversial in nutrition
Joe asks for a plain-language explanation of epidemiology. Kahn defends it as one pillar of evidence among others, while Kresser argues nutrition epidemiology often starts with flawed assumptions and yields weak, confounded associations.
- •Kahn’s “four-pillar” evidence stack: basic science → epidemiology → RCTs → centenarian/Blue Zone observations
- •Limits of observational datasets: incomplete lifestyle info and difficulty isolating variables
- •Kresser’s definition of observational nutrition studies and why causality is hard to infer
- •Discussion of why some questions (e.g., smoking) can’t be tested with RCTs
- 11:51 – 30:02
Kresser’s three big epidemiology problems: bad dietary recall, healthy-user bias, and tiny risk signals
Kresser lays out a structured critique: questionnaires are unreliable, health-conscious behaviors cluster (confounding), and typical nutrition relative risks are often too small to distinguish from chance. This frames later disputes about meat, cancer, and fat guidelines.
- •Food-frequency questionnaires rely on memory and under-reporting (especially among overweight participants)
- •‘Healthy user bias’: people who follow ‘unhealthy’ habits often stack multiple unhealthy behaviors
- •Most nutrition relative risks are small (e.g., ~18%) compared with smoking and other strong signals
- •Media often reports association as causation, amplifying weak findings into clickbait
- 30:02 – 37:36
Processed meat and cancer: WHO/IARC claims vs. context and absolute risk
They debate what the WHO processed-meat classification means in practice. Kahn emphasizes population-level consequences even from small risk increases; Kresser stresses context (vegetables, cooking methods) and confounding in typical processed-meat eaters.
- •Kahn highlights WHO/IARC’s ‘processed meat causes cancer’ stance and potential public-health impact
- •Kresser notes the reported increases are small and often conflated with other unhealthy behaviors
- •Mechanisms discussed: nitroso compounds, heterocyclic amines, heme iron, and how plants/spices may mitigate effects
- •Practical takeaway they both lean toward: reduce ultra-processed meats and pair meals with vegetables
- 37:36 – 39:25
Practical ‘harm reduction’ tips: veggies with meat, marinades, and cooking chemistry
Kahn pivots to actionable advice: increasing vegetable intake can blunt some negative acute vascular effects of typical meals. They discuss how cooking methods and marinades can change formation of potentially harmful compounds.
- •‘Meat with vegetables is safer than meat without vegetables’ (shared partial agreement)
- •Grilling and compounds like AGEs; marinades can reduce harmful byproducts
- •Example: hospital burger study and endothelial/artery function changes after meals
- •Broad recommendation: prioritize vegetables and whole foods regardless of dietary camp
- 39:25 – 44:52
The saturated fat showdown begins: why guidelines still say ‘limit it’
Joe pushes them into the central dispute: saturated fat and cholesterol guidance. Kahn argues global medical societies converge on limiting saturated fat based on biochemistry, metabolic ward studies, and population observations; Kresser argues newer meta-analyses don’t support the feared outcomes.
- •Kahn’s historical framing: rise of heart disease, Framingham, Ancel Keys, and the shift to saturated fat focus
- •Biochemical claim: saturated fat lowers LDL receptor activity → higher LDL in blood → atherosclerosis risk
- •Kahn appeals to guideline consensus (WHO/AHA/ACC and others)
- •Kresser counters: meta-analyses and RCT reviews show no clear saturated-fat–CVD link in outcomes
- 44:52 – 1:45:20
Meta-analyses vs. mechanistic biology: what counts as ‘best evidence’
They clash over evidence hierarchy. Kresser leans on meta-analyses of RCTs and large cohort reviews; Kahn argues meta-analyses can be manipulated and insists mechanisms and multiple evidence streams must align, citing Cochrane and Mendelian randomization work.
- •Kresser: observational data generates hypotheses; RCTs and meta-analyses should confirm/refute
- •Kahn: some influential meta-analyses (e.g., “Butter is back”) are flawed or industry-influenced
- •Debate over Cochrane 2015 (Hooper) conclusions and what endpoints matter (mortality vs. CVD events)
- •Kahn introduces Mendelian randomization: lifelong low LDL genetically linked to lower ASCVD risk
- 1:45:20 – 1:55:58
Guidelines, conflicts of interest, and whether institutions lag behind science
Joe repeatedly asks why major organizations keep recommending saturated fat limits if newer analyses disagree. Kresser argues institutions can be behind the curve and face industry conflicts; Kahn acknowledges funding problems but maintains consensus guidance reflects the best integrated evidence.
- •Kresser: guideline bodies may lag new reviews; cites process issues in guideline evidence use
- •Conflicts of interest: big-food sponsorship at health organizations and conferences
- •Kahn: industry funding pervades nutrition research, but doesn’t invalidate the overall consensus by itself
- •Dispute over what USDA guidance actually changed (total fat vs. cholesterol language)
- 1:55:58 – 2:01:53
Individual variation and dietary context: saturated fat with sugar, eggs, and “nutrivore” framing
Kresser clarifies he’s not claiming saturated fat affects no one—some individuals are hyper-responders—but argues average outcomes don’t show the feared risks, especially in whole-food contexts. They explore why saturated fat plus refined carbs may be particularly problematic and briefly detour into eggs/cholesterol evidence.
- •Context effect: refined carbs + high insulin can shift fat storage/oxidation and worsen markers
- •Where saturated fat comes from in typical American diets (often ultra-processed foods)
- •Eggs and dietary cholesterol: dispute over how often they raise serum cholesterol and how to interpret newer reviews
- •Kresser’s stance: focus on endpoints (heart attacks, mortality), not just intermediary mechanisms
- 2:01:53 – 2:12:14
Aging pathways and animal vs. plant protein: mTOR/IGF-1, mechanisms vs. outcomes
Kahn argues animal amino acid profiles (e.g., methionine/leucine) activate aging-related pathways (mTOR/IGF-1), tying this to observational findings on animal vs. plant protein and cancer risk. Kresser challenges mechanistic inference unless it consistently shows up in hard outcomes across robust evidence syntheses.
- •Kahn: mTOR/IGF-1 and related pathways as a rationale for limiting animal protein, especially with high-sugar diets
- •Claimed observational associations: higher animal protein linked to higher cancer/mortality risk vs. plant protein
- •Kresser: mechanistic plausibility isn’t enough; outcomes data on fresh red meat often shows weak or null associations
- •Back-and-forth on single-study citations vs. systematic reviews/meta-analyses and confounding control
- 2:12:14 – 3:47:38
Back to LDL biology: receptors, statins, PCSK9, and emerging markers like TMAO
Kahn re-centers the cardiology model: LDL receptor biology, pharmacology (statins, PCSK9 inhibitors), and the clinical framing of lowering LDL early for lifelong benefit. He then tees up newer biomarkers (TMAO) as the discussion approaches the frontier of cardiometabolic risk research.
- •LDL receptor discovery and its role in cholesterol metabolism and ASCVD risk framing
- •Clinical translation: statins, PCSK9 inhibitors, and plaque/risk reduction claims
- •Argument that human physiology (LDL handling) hasn’t ‘changed,’ only tools and therapies have expanded
- •Introduction of TMAO (newer risk marker) as the transcript segment ends mid-explanation
